News Column

Qu Biologics Granted U.S. Patent for Use of E. coli to Treat Colon Cancer

June 2, 2014



By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's immune system, announced it has been granted a U.S. patent covering the use of immunotherapies derived from components of E. coli to treat colon cancer.

Qu Biologics was issued U.S. Patent No. 8,501,198. The allowed claims relate to the use of E. coli components to stimulate an immune response to treat colon cancer. This latest patent follows Qu Biologics' first U.S. issued patent for the use of K. pneumoniae derived immunotherapies for the treatment of lung cancer.

Dr. Hal Gunn, Chief Executive Officer of Qu Biologics commented, "We are very pleased to have been granted another important cancer immunotherapy patent. Our SSIs aim to address the underlying immunological causes of chronic inflammatory diseases, representing a novel treatment approach that stimulates the body's own immune response to cancer. We will continue to further strengthen our patent position as we prepare for our first clinical trial in cancer to augment our current clinical trial in Crohn's disease."

Qu Biologics develops immunotherapies called Site Specific Immunomodulators (SSIs), which are derived from components of bacteria and are aimed at stimulating the body's immune system to treat cancer and immune-related disease. The company's SSI platform represents a promising new approach to the treatment of cancer and immune-related disease by addressing the immunological defect/deficiency that underlies these diseases. Qu Biologics has developed multiple SSIs, each of which targets a specific tissue/organ system (see also Clinical Trials and Studies).

Keywords for this news article include: Oncology, Escherichia, Immunotherapy, Immunomodulation, Enterobacteriaceae, Gammaproteobacteria, Clinical Trials and Studies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Vaccine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters